WILMINGTON — Incyte Corporation, based in Wilmington, has announced the first patient has been treated in the REACH-1 pivotal Phase 2 trial evaluating its ruxolitinib drug, trademarked Jakafi. The drug […]
© 2024 Delaware Business Times
Important notice for access to your Delaware Business Times “Insider” content
Flash Sale! Subscribe to Delaware Business Times and save 50%.
Limited time offer. New subscribers only.
SUMMER FLASH SALE!
Subscribe to Delaware Business Times and save 50%